Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Maybe try reading the news release? Right your one of those
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(310)
•••
Comment by AngelaLon Jan 17, 2021 4:38pm
248 Views
Post# 32316097

RE:RE:RE:RE:RE:RE:RE:RE:Maybe try reading the news release? Right your one of those

RE:RE:RE:RE:RE:RE:RE:RE:Maybe try reading the news release? Right your one of thoseBoth Pfizer and Moderna have confirmed this week that the Brazilian strain is not responsive to convalescent serum after their vaccinations. As a consequence, the U.K. government, and now other countries, has completely shut down entry of visitors from Brazil, Portugal, and South American countries bordering Brazil. The strain from Brazil has emerged in the last two weeks as the number one global threat of Covid-19 infection because there is no vaccine existing. Development of a novel mRNA vaccine is a daunting task, requiring a minimum study of 20,000 subjects necessitated by the FDA, EMEA, and MHRA, as has been demanded for all the current vaccines approved and in development. The more worrisome feature is that the Brazilian strain may be a harbinger of more mutant strains that are able to evade current vaccines.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities